PD1 and PD-L1 status, assessed by IHC staining, has been identified as a biomarker associated with a higher chance of tumor response in patients treated with anti-PD-L1 antibodies and a better OS in multiple tumor types [12]. Here, CD274 is linked to neoplasm.